NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q1 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $239,000 | -29.7% | 61,100 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $340,000 | -56.7% | 61,100 | +10.1% | 0.00% | -50.0% |
| Q4 2021 | $786,000 | -19.4% | 55,500 | +2.8% | 0.00% | -33.3% |
| Q3 2021 | $975,000 | +4.5% | 54,000 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $933,000 | -11.1% | 54,000 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $1,050,000 | +6.6% | 54,000 | 0.0% | 0.00% | -25.0% |
| Q4 2020 | $985,000 | +4.7% | 54,000 | -4.8% | 0.00% | 0.0% |
| Q3 2020 | $941,000 | -40.7% | 56,700 | -35.6% | 0.00% | -60.0% |
| Q3 2019 | $1,587,000 | -71.9% | 88,008 | -45.8% | 0.01% | -64.3% |
| Q2 2019 | $5,656,000 | -11.5% | 162,316 | +69.2% | 0.03% | -26.3% |
| Q1 2019 | $6,390,000 | +121.6% | 95,942 | +11.4% | 0.04% | +100.0% |
| Q4 2018 | $2,884,000 | -54.9% | 86,093 | -10.3% | 0.02% | -50.0% |
| Q3 2018 | $6,390,000 | +33.2% | 95,942 | -3.0% | 0.04% | +22.6% |
| Q2 2018 | $4,799,000 | -27.2% | 98,904 | +57.5% | 0.03% | -31.1% |
| Q1 2018 | $6,595,000 | +521.0% | 62,800 | +15.4% | 0.04% | +462.5% |
| Q4 2017 | $1,062,000 | 0.0% | 54,400 | 0.0% | 0.01% | 0.0% |
| Q3 2017 | $1,062,000 | +1.0% | 54,400 | 0.0% | 0.01% | 0.0% |
| Q2 2017 | $1,052,000 | -16.8% | 54,400 | 0.0% | 0.01% | -33.3% |
| Q1 2017 | $1,265,000 | +394.1% | 54,400 | +159.0% | 0.01% | +300.0% |
| Q4 2016 | $256,000 | -22.2% | 21,000 | +8.2% | 0.00% | -25.0% |
| Q3 2016 | $329,000 | +21.4% | 19,400 | 0.0% | 0.00% | +33.3% |
| Q2 2016 | $271,000 | -65.2% | 19,400 | -66.2% | 0.00% | -66.7% |
| Q1 2016 | $779,000 | -32.6% | 57,400 | -14.7% | 0.01% | -30.8% |
| Q4 2015 | $1,155,000 | +59.1% | 67,300 | +1.7% | 0.01% | +44.4% |
| Q3 2015 | $726,000 | -9.1% | 66,200 | +3.6% | 0.01% | 0.0% |
| Q2 2015 | $799,000 | +17.8% | 63,900 | +3.7% | 0.01% | +12.5% |
| Q1 2015 | $678,000 | -35.3% | 61,600 | -9.7% | 0.01% | -38.5% |
| Q4 2014 | $1,048,000 | +16.6% | 68,200 | -8.5% | 0.01% | +8.3% |
| Q3 2014 | $899,000 | -3.4% | 74,500 | +2.6% | 0.01% | -14.3% |
| Q2 2014 | $931,000 | +9.5% | 72,600 | +3.6% | 0.01% | 0.0% |
| Q1 2014 | $850,000 | +11.3% | 70,100 | +6.2% | 0.01% | +7.7% |
| Q4 2013 | $764,000 | +13.4% | 66,000 | +2.3% | 0.01% | +8.3% |
| Q3 2013 | $674,000 | – | 64,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |